BMRN — BioMarin Pharmaceutical Inc. stock price and chart

Share this page

BMRN

$57.18-2.16%

as of close, Oct 2, 2026

☾ AH $57.18 -2.16%

BioMarin Pharmaceutical Inc.Stock · Health CareNasdaq Composite 0.02%Russell 1000 0.02%US Stock Market 0.02%Russell 3000 0.01%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

60.070.080.090.0100.0110.0120.0020.0M40.0M$57.18

2026-10-02

Price$57.18

MA20$59.10

MA50$57.41

Vol12.0M

What would $1,000 invested in BMRN be worth today? →

BMRN returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $57.18
Change YTD: -3.79%
Next earnings: Oct 26, 2026
Market cap: 11.1B2016-12 14.2B2026-10 11.1B-22.3% over the window
Enterprise value: 14.4B
Shares outstanding: 193.6M2016-06 163.5M2026-06 193.6M+18.4% over the window
52W low: $49.26
52W high: $70.98
From 52W high: -19.44%
From 52W low: +16.08%
52W range: 36%
Beta: 0.23

Volume

Rel volume: 1.14×
30D volume: 1.9M
30D $ vol: 123.1M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3M0 insider-days of buying (no priced lot) and 1 of selling ($1.2M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$1.2M
Insider net 1Y0 insider-days of buying (no priced lot) and 5 of selling ($4.3M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$4.3M

Form 4 transactions by trade date, as filed; latest on file 2026-09-02.

Fundamentals

Sales (ttm): 3.4B2016-06 973.7M2026-06 3.4B+249.9% over the window
Sales/share: $17.602016-06 $5.962026-06 $17.60+195.4% over the window
EPS (ttm): $0.372016-09 -$2.812026-06 $0.37-113.3% over the window
FCF (ttm): 738.2M2016-06 -505M2026-06 738.2M-246.2% over the window
FCF/share: $3.812016-06 -$3.092026-06 $3.81-223.4% over the window
Book value/share: $32.662016-06 $11.732026-06 $32.66+178.4% over the window
Net margin: 2.14%2016-06 -53.9%2026-06 2.1%-104.0% over the window
ROE: 1.15%2016-06 -27.3%2026-06 1.2%-104.2% over the window
ROA: 0.62%2016-06 -17.0%2026-06 0.6%-103.7% over the window
Debt / equity: 0.56×2025-12 0.102026-06 0.56+468.8% over the window
Current ratio: 2.392016-06 3.032026-06 2.39-21.3% over the window

Growth (CAGR, ttm) · 10Y

Sales: +11.20%2025-06-30 → 2026-06-303.1B → 3.4B (+11.2% total)+15.09%2023-06-30 → 2026-06-302.2B → 3.4B (+52.5% total)+12.19%2021-06-30 → 2026-06-301.9B → 3.4B (+77.7% total)+13.34%2016-06-30 → 2026-06-30973.7M → 3.4B (+249.9% total)
Net income: -88.91%2025-06-30 → 2026-06-30657.2M → 73M (-88.9% total)-9.97%2023-06-30 → 2026-06-30100M → 73M (-27.0% total)-38.54%2021-06-30 → 2026-06-30832.1M → 73M (-91.2% total)n/a
FCF: +6.23%2025-06-30 → 2026-06-30694.9M → 738.2M (+6.2% total)+144.93%2023-06-30 → 2026-06-3050.2M → 738.2M (+1370.2% total)+33.61%2021-06-30 → 2026-06-30173.4M → 738.2M (+325.7% total)n/a
Shares: +0.81%2025-06-30 → 2026-06-30192M → 193.6M (+0.8% total)+0.95%2023-06-30 → 2026-06-30188.2M → 193.6M (+2.9% total)+1.09%2021-06-30 → 2026-06-30183.4M → 193.6M (+5.6% total)+1.71%2016-06-30 → 2026-06-30163.5M → 193.6M (+18.4% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -88.85%2025-06-30 → 2026-06-30$3.34 → $0.37 (-88.8% total)-11.09%2023-06-30 → 2026-06-30$0.53 → $0.37 (-29.7% total)-39.08%2021-06-30 → 2026-06-30$4.44 → $0.37 (-91.6% total)n/a
Sales/share: +10.31%2025-06-30 → 2026-06-30$15.96 → $17.60 (+10.3% total)+14.01%2023-06-30 → 2026-06-30$11.87 → $17.60 (+48.2% total)+10.98%2021-06-30 → 2026-06-30$10.45 → $17.60 (+68.4% total)+11.44%2016-06-30 → 2026-06-30$5.96 → $17.60 (+195.4% total)
FCF/share: +5.37%2025-06-30 → 2026-06-30$3.62 → $3.81 (+5.4% total)+142.63%2023-06-30 → 2026-06-30$0.27 → $3.81 (+1329.2% total)+32.17%2021-06-30 → 2026-06-30$0.95 → $3.81 (+303.2% total)n/a
Book value/share: +4.05%2025-06-30 → 2026-06-30$31.39 → $32.66 (+4.0% total)+8.71%2023-06-30 → 2026-06-30$25.42 → $32.66 (+28.5% total)+7.17%2021-06-30 → 2026-06-30$23.11 → $32.66 (+41.3% total)+10.78%2016-06-30 → 2026-06-30$11.73 → $32.66 (+178.4% total)
Price: +2.90%2025-10-02 → 2026-10-02$55.57 → $57.18 (+2.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-13.08%2023-10-02 → 2026-10-02$87.08 → $57.18 (-34.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.82%2021-10-01 → 2026-10-02$77.16 → $57.18 (-25.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-4.70%2016-09-30 → 2026-10-02$92.52 → $57.18 (-38.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +2.90%2025-10-02 → 2026-10-02$55.57 → $57.18 (+2.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-13.08%2023-10-02 → 2026-10-02$87.08 → $57.18 (-34.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.82%2021-10-01 → 2026-10-02$77.16 → $57.18 (-25.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-4.70%2016-09-30 → 2026-10-02$92.52 → $57.18 (-38.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 153.4×2016-12 -30.262026-10 151.68-601.3% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 74.2×2016-12 -23.262026-10 74.16-418.8% over the window
Fwd P/E: 9.0×
P/S (ttm)Market cap ÷ TTM revenue.: 3.2×2016-12 13.642026-10 3.25-76.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.8×2016-12 5.382026-10 1.75-67.5% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 15.0×2016-12 -28.842026-10 14.99-152.0% over the window
EV/EBITDA (fy): 47.7×
EV/Sales (ttm): 4.2×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 6.67%2016-09 -3.5%2026-06 6.7%-292.2% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 193.6M ÷ 192.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.81%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.81%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($10.6B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -0.81%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($11.1B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 -5.0%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($11.1B). Same caveat as the cash buyback yield.: 0.00%2016-09 -5.0%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 67th
P/OI: 42nd
P/S: 2nd
P/B: 5th
P/FCF: 10th

Bar = where today’s multiple sits in BMRN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-02

-2.16%

-5.11%

-14.62%

-3.07%

YTD

-3.79%

+2.90%

-25.89%

Recent filings

Sep 308-K · Material definitive agreement
Sep 158-K · Other events
Sep 148-K · Directors or officers; compensation
Sep 2Insider sale · Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares for $1.2M at $66.28
Sep 18-K · Other events

All filings and insider trades →

Financial statements

Open full BMRN financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-13.21%	-0.04%
NVO	Novo Nordisk A/S	-20.21%	-0.21%
SNY	Sanofi ADS	-10.23%	-1.84%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-6.76%	-0.32%
NTRA	Natera Inc.	+26.20%	+0.46%
ARGX	argenx SE American Depositary Shares	-12.90%	-1.79%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	-3.09%	+0.00%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+5.44%	+0.56%

BMRN — BioMarin Pharmaceutical Inc. price, chart and key statistics